Tempus AI, Inc. (TEM)
Nasdaq · Healthcare · Health Information Services
$83.55+9.03%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $15.1B
- 52-week range
- $40.77 – $104.32
- 52-week change
- −17.67%
- EPS (trailing)
- −$1.44
- Analyst rating
- 2.2 Buy
- Next earnings
- Nov 3, 2026
Fiscal year to Dec 2025
- Revenue
- $1.3B (+83.42%)
- Net income
- −$245M
- Operating margin
- −19.9%
- Diluted EPS
- −$1.41
- Free cash flow
- −$239M
From the company’s annual report on SEC EDGAR.
About Tempus AI, Inc.
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses.
Headquarters: Chicago, United States · 3,800 employees · tempus.com